Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix and BAL2062 -- ...

Expands available market to include over 200 children’s hospitals in the United StatesLEXINGTON, Mass., Sept. 16, 2024 (GLOBE ...

Basilea Pharmaceutica has entered into a multi-year agreement with the Biomedical Advanced Research and Development Authority ...

Moreover, children with invasive candidiasis present a significant burden to the U.S. healthcare system, with a mean increased hospital length of stay of 21 days and approximately $92,000 in ...

Moreover, children with invasive candidiasis present a significant burden to the U.S. healthcare system, with a mean increased hospital length of stay of 21 days and approximately $92,000 in excess ...

Initial funding of USD 29 million to support development of Basilea's clinical stage first-in-class antifungals, fosmanogepix a ...

The present article reviews these aspects for invasive aspergillosis and invasive candidiasis, the two most common life-threatening fungal infections. Among immunosuppressed children, the impact ...

Without immediate action, humanity will face a potentially disastrous escalation in resistance in fungal disease, a renowned ...

The pathogens considered most dangerous to human health included Aspergillus fumigatus, which comes from mold and infects the ...

Critically ill patients are at risk of developing both acute kidney injury (AKI) and invasive fungal infections (IFIs ... as this will provide broad-spectrum antifungal treatment against candidiasis, ...